The role of radiation therapy for de novo metastatic bladder and renal cancers - Institut de cancérologie de l'Ouest Access content directly
Journal Articles Cancer/Radiothérapie Year : 2024

The role of radiation therapy for de novo metastatic bladder and renal cancers

Abstract

Metastatic bladder and renal cancers account respectively for 2.1% and 1.8% of cancer deaths worldwide. The advent of immune checkpoint inhibitors has revolutionized the management of metastatic disease, by demonstrating considerable improvements in overall survival. However, despite initial sensitivity to immune checkpoint inhibitors for most patients, both bladder and renal cancer are associated with short progression-free survival and overall survival, raising the need for further strategies to improve their efficacy. Combining systemic therapies with local approaches is a longstanding concept in urological oncology, in clinical settings including both oligometastatic and polymetastatic disease. Radiation therapy has been increasingly studied with either cytoreductive, consolidative, ablative or immune boosting purposes, but the long-term impact of this strategy remains unclear. This review intends to address the impact of radiation therapy with either curative or palliative intent, for synchronous de novo metastatic bladder and renal cancers.
Embargoed file
Embargoed file
Visibility date is undetermined

Dates and versions

inserm-04517309 , version 1 (22-03-2024)

Licence

Copyright

Identifiers

Cite

P. Sargos, J. Le Guevelou, J. Khalifa, L. Albiges, D. Azria, et al.. The role of radiation therapy for de novo metastatic bladder and renal cancers. Cancer/Radiothérapie, 2024, 28 (1), pp.56 - 65. ⟨10.1016/j.canrad.2023.02.004⟩. ⟨inserm-04517309⟩
27 View
5 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More